Page 2 - Corp Comms News Today

Refresh for updates…Nathaniel Brown is departing Warner Bros Discovery as their Corp Comms Chief, Deadline has learned. It is an amicable departure we hear.…

Warner Bros Discovery Corp Comms Chief Nathaniel Brown Exiting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2023 -- Merus N.V. , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced updated...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: BMO Biopharma Spotlight Series: Oncology Day (fireside chat): Wednesday, November 8 at 11:30-11:55 a.m. ET (No live...

/CNW/ - Hudsons Bay and Student Price Card (SPC) are thrilled to launch a new partnership, offering enhanced benefits and exclusive offers to SPCs student...

(2023-10-23 | NDAQ:MRUS) Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

Zeno interim clinical data continues to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions Petosemtamab 2L+ HNSCC phase 3 trial design supported

Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: MCLA-129 in previously treated head & neck squamous cell carcinoma UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), tod...

Planview positioned highest in execution and furthest in vision

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", the "Company," "we" and "our"), a clinical-stage oncology company developing innovative, full-length